SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
___________________
Date of Report (Date of earliest event reported) March 22, 1999
BIOCONTROL TECHNOLOGY, INC.
(Exact name of registrant as specified in its charter)
Pennsylvania 0-10822 25-1229323
(State of other jurisdiction (Commission File Number) (IRS Employer
of incorporation) Identification No.)
300 Indian Springs Road, Indiana, Pennsylvania 15701
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code (412) 349-1811
_________________________________________________________________
(Former name or former address,
if changes since last report.)
Item 1. Change in Control of Registrant.
Not applicable.
Item 2. Acquisition or Disposition of Assets.
Not applicable.
Item 3. Bankruptcy or Receivership.
Not applicable.
Item 4. Changes in Registrant's Certifying Accountant
Not applicable.
Item 5. Other Events.
Biocontrol Technology, Inc. announced today, in follow-
up to its February 9, 1999 release, that on March 23
and 24, 1999 members of the US Food and Drug
Administration (FDA) staff will attend a seminar at
Biocontrol's Indiana, PA facility on the use and
maintenance of the Diasensor 1000 noninvasive glucose
sensor purchased from the Biocontrol in February. The
seminar is designed to educate the FDA staff regarding
the Diasensor 1000 so they can evaluate its performance
characteristics and conduct laboratory research on
noninvasive monitoring.
Item 6. Resignation of Registrant's Directors.
Not Applicable
Item 7. Financial Statement, Pro Forma Financial Information
and Exhibits.
(a) Financial Statements and Businesses Acquired - Not
Applicable.
(b) Pro Forma Financial Information - Not Applicable.
(c) Exhibits - Press Release.
SIGNATURES
Pursuant to the requirement of the Securities Exchange Act
of 1934, the Registrant has duly caused this Report to be signed
on its behalf by the undersigned hereunto duly authorized.
BIOCONTROL TECHNOLOGY, INC.
by /s/ Fred E. Cooper
Fred E. Cooper, CEO
DATED: March 22, 1999
BICO
BIOCONTROL TECHNOLOGY, INC
2275 Swallow Hill Road, Building 2500
Pittsburgh, PA 15220
Press Release
Investors Media
Diane McQuaide Susan Taylor
1.412.429.0673 phone 1.412.429.0673 phone
1.412.279.9690 fax 1.412.279.5041 fax
BIOCONTROL TO HOST SEMINAR FOR FDA STAFF
Pittsburgh, PA - March 22, 1999 - Biocontrol Technology,
Inc. (OTCBB:BICO) announced today, in follow-up to its February
9, 1999 release, that on March 23 and 24, 1999 members of the US
Food and Drug Administration (FDA) staff will attend a seminar at
Biocontrol's Indiana, PA facility on the use and maintenance of
the Diasensorr 1000 noninvasive glucose sensor purchased from
Biocontrol in February.
The seminar is designed to educate the FDA staff regarding
the Diasensor 1000 so they can evaluate its performance
characteristics and conduct laboratory research on noninvasive
monitoring. The seminar will include discussions on the science
behind the Diasensor as well as on the calibration, operation,
intended use, software involved, and the actual operation of the
Diasensor.
The Diasensor 1000 is a home-use instrument used by patients
with diabetes to measure their blood glucose without the need to
prick the finger to obtain a drop of blood. Patients using
currently marketed invasive devices require that patients prick
their fingers to obtain a sample of blood to test their glucose.
The Diasensor 1000 illuminates a small area on the patient's arm
with infrared light, which is then scattered back out through the
skin and collected by the instrument. This information is
interpreted by software in the instrument as a blood glucose
concentration.
Although not approved for sale in the US, the Diasensor 1000
is available in the 15-nation European Union where it has been
approved.
Biocontrol Technology has its corporate offices in
Pittsburgh, PA and is involved in the development and manufacture
of biomedical devices and environmental products. Subsidiary
Diasensor.com, Inc., also located in Pittsburgh, PA, markets the
Diasensor. Diasensor.com owns the patent, marketing and
distribution rights to the sensor while Biocontrol has the
exclusive rights to the research and development and
manufacturing of the sensor.
WEBSITE: www.bico.com
INVESTOR RELATIONS NEWSLINE NUMBER: 1.800.357.6204
